Ignite Creation Date:
2024-05-05 @ 11:53 PM
Last Modification Date:
2024-10-26 @ 10:41 AM
Study NCT ID:
NCT01440920
Status:
COMPLETED
Last Update Posted:
2021-03-08
First Post:
2011-09-15
Brief Title:
A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients
Sponsor:
Otsuka Pharmaceutical Co Ltd
Organization:
Otsuka Pharmaceutical Co Ltd
Study Overview
Official Title:
A Phase I Study of OCV-501 in the Treatment of Patients With Acute Myeloid Leukemia
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety tolerability of OCV-501 in patients with acute myeloid leukemia AML who achieved complete remission after induction regimen and who completed a standard consolidation therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| JapicCTI-111623 | OTHER | JAPIC | None |